GO
Loading...

Pfizer Inc

More

  • Midday Glance: Pharmaceuticals companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Baxter International Inc. rose$. 93 or 1.2 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 41 or. 8 percent, to $49.33. Hospira rose$. 27 or. 5 percent, to $50.74.

  • Dems press blocks on corporate tax inversions plans Tuesday, 22 Jul 2014 | 8:35 AM ET

    Democrats, searching for campaign issues before November's congressional elections, have jumped on inversions, and several of them have offered bills that would curb the deals.

  • Early Glance: Pharmaceuticals companies Monday, 21 Jul 2014 | 11:37 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $76.15. Bristol-Myers Squibb Co. fell$. 28 or. 6 percent, to $48.84. Hospira fell$. 06 or. 1 percent, to $50.09.

  • July 18- Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the company at about $2.57 billion at the top end. The company's major customers include Pfizer Inc, Johnson& Johnson, GlaxoSmithKline Plc, Merck& Co Inc and Novartis AG.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • Midday Glance: Pharmaceuticals companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $76.53. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $48.63. Hospira fell$. 17 or. 3 percent, to $50.58.

  • Most active New York Stock Exchange-traded stocks Wednesday, 16 Jul 2014 | 2:54 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. AbbVie fell. 6 percent to $53.14 with 13,607,100 shares traded. Advanced Micro Devices Inc. rose 2.7 percent to $4.65 with 46,059,000 shares traded.

  • ZURICH, July 16- Roche's experimental drug crenezumab failed to delay a decline in thinking and memory skills in people with Alzheimer's disease, a result likely to bolster a growing belief that drugs need to be given in earlier stages of the disease to show a benefit.

  • Roche Alzheimer's drug fails main goals in mid-stage study Wednesday, 16 Jul 2014 | 11:30 AM ET

    ZURICH, July 16- Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

  • Early Glance: Pharmaceuticals companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Baxter International Inc. fell$. 09 or. 1 percent, to $76.67. Bristol-Myers Squibb Co. rose$. 17 or. 3 percent, to $48.88. Hospira rose$. 04 or. 1 percent, to $50.79.

  • Genentech Alzheimer's drug misses goals in studies Wednesday, 16 Jul 2014 | 11:00 AM ET

    Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people. Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

  • July 16- The Obama administration urged Congress on Wednesday to act to stem what it described as a growing trend in which U.S. companies move their headquarters abroad to reduce their U.S. tax bills. "Congress should enact legislation immediately," Treasury Secretary Jack Lew told a business conference in New York hosted by cable television channel CNBC.

  • July 16- Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.

  • Jack Lew pushes for crackdown on tax inversions Wednesday, 16 Jul 2014 | 6:19 AM ET
    Jack Lew, U.S. Treasury Secretary.

    Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.

  • Novartis, Google to make 'smart' contact lenses Tuesday, 15 Jul 2014 | 1:18 PM ET
    Google smart contact lens to measure glucose levels in tears.

    Novartis and Google have agreed to develop "smart" contact lenses to help diabetics track blood glucose levels or restore the eye's ability to focus.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.

  • US corporations make big money, cut out on taxes Monday, 14 Jul 2014 | 12:03 PM ET

    Big U.S. corporations are benefiting from a "new exceptionalism," allowing them to skip out on their domestic tax bills, The Washington Post says.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • *AbbVie raises bid to 53.20/ share from 51.15. *Bid comprises 24.44 stg cash and 0.8960 new AbbVie shares. LONDON, July 14- London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc on Monday, signaling the conclusion to a long-running courtship largely motivated by tax.